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INTRODUCTION
Recent advances in cancer biology have identified a number 
of biomarkers for the diagnosis and prognosis of cancer.1-4 These 
biomarkers not only can predict the prognosis of patients, but 
they also can indicate potential responses to treatment, such 
as radiotherapy (RT), chemotherapy, and surgery. For example, 
patients who are expected to have a favorable response to RT 
could avoid excessive toxicities by dose de-escalation; con-
versely, a dose escalation strategy might be considered for pa-
tients who are expected to have a poor response to treatment 
to improve tumor control.5 Bauman, et al.6 reviewed the litera-
ture on radiobiology-associated biomarkers for tumor respons-
es, including cancer stem cell markers, phosphorylated histone 
H2AX, p16 protein expression, positron emission tomography 
imaging with [F-18] fluoromisonidazole, and hypoxia-specific 
gene arrays, related with the mechanisms of radioresistance 
and radiosensitivity.
Cell-free DNA (cfDNA) has garnered attention as a promising 
biomarker, since the abnormalities of cfDNA were identified 
in patients with cancer.2 In addition to the relative ease of quan-
tifying cfDNA levels, the development of next-generation se-
quencing (NGS) has provided powerful and comprehensive 
genetic information on cancer, allowing for the application of 
specific genomic analysis of cfDNA.7-9 Compared to a tradition-
al invasive biopsy, a “liquid biopsy” including cfDNA may be 
easier to use and preferable for patients with hepatocellular 
carcinoma (HCC) because of HCC’s rich blood supply and vas-
cular structure, which pose a greater risks for complications 
with invasive biopsy.10 However, limited reports on the clinical 
significance of cfDNA in RT are available for non-small cell lung 
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cancer,11 head and neck cancer,12 and pancreatic cancer.13 To our 
knowledge, no studies have reported the prognostic or predic-
tive value of cfDNA in patients who received RT for HCC. Thus, 
we investigated the feasibility of quantitative analysis and the 
clinical significance of cfDNA in patients with HCC treated 
with RT.
MATERIALS AND METHODS
Patient selection and treatment protocol
A total of 61 patients who received RT for HCC at Yonsei Can-
cer Center between June 2011 and April 2015 were recruited 
from two prospective studies.14 One study cohort consisted of 
patients who underwent conventionally fractionated RT 
(CFRT), whereas the other cohort consisted of patients who re-
ceived stereotactic body radiation therapy (SBRT) for HCC. The 
diagnosis of HCC was based on the American Association for 
Study of Liver Diseases criteria; tumor, node and metastasis 
(TNM) staging was classified according to the modified Union 
for International Cancer Control (mUICC). We excluded pa-
tients with insufficient blood samples (n=3), incomplete RT 
(n=2), and primary tumors other than HCC (n=1). Ultimately, 
55 patients with HCC were included. This study protocol con-
formed to the Declaration of Helsinki of 1975 as revised in 1983, 
and was approved by the Institutional Review Board of Yonsei 
University Health System (4-2010-0566 and 4-2011-0650). All 
55 patients provided informed consent, and were followed up 
until February 2017.
At our institution, the best treatment option is determined 
through multidisciplinary discussion. We selected RT as a local 
treatment option for patients who had contraindications for 
surgery, transarterial chemoembolization, or other local treat-
ments. All 55 patients in both prospective cohort studies re-
ceived RT, either with a definitive or salvage aim. The patients 
in one study cohort underwent CFRT for relatively large and 
multiple lesions, whereas those in the other study cohort re-
ceived SBRT for smaller lesions (<4 cm), solitary lesions, and 
lesions that were sufficiently distant from critical organs. 
The CFRT modality was chosen according to each patient’s 
preference, whereas intensity-modulated RT using a helical to-
motherapy device (TomoTherapy, Madison, WI, USA) was the 
sole modality for the patients who received SBRT. In the CFRT 
group, a total dose of 45 Gy in 25 fractions was routinely used. 
If the tumor location was sufficiently distant from dose-limit-
ing organs, a radiation dose of >45 Gy was considered on an 
individual basis. In case of patients with regional lymph node 
(LN) metastases, the nodal areas were also included in RT tar-
get volume. Concurrent chemotherapy consisted of 5-fluoro-
uracil (500 mg/day for 5 hours on 5 consecutive days through 
an implanted intra-arterial port system) during the first and 
last week of RT, followed by adjuvant chemotherapy with he-
patic arterial infusion chemotherapy with 5-fluorouracil (500 
mg/m2 for 5 hours on 3 consecutive days) and cisplatin (60 mg/
m2 for 2 hours on a single day). Surgical excision was consid-
ered after RT if the tumor became resectable. In the SBRT group, 
an ablative dose of 60 Gy in four fractions was adopted; no pa-
tients in this group received concurrent or adjuvant chemo-
therapy. After the scheduled treatment was complete, regular 
follow-up imaging was conducted every 1−3 months.
Sample collection
Blood (5−10 mL) was collected from the patients before and af-
ter RT. In the CFRT group, post-treatment blood sampling was 
carried out on the day concurrent chemoradiotherapy finished 
(before the start of following adjuvant chemotherapy), while 
the sample was collected on the end date of RT in the SBRT 
group. The blood samples were collected in Vacutainer tubes 
(BD Biosciences, Franklin Lakes, NJ, USA) containing Ethyl-
enediaminetetraacetic acid (EDTA) using aseptic measures, 
and were centrifuged at 3000 rpm for 10 min at 4°C to separate 
buffy coats and plasma. An additional centrifugation for 10 min 
was performed to produce cell-free plasma. Plasma aliquots 
were immediately frozen at -80°C until cfDNA purification. 
Cell-free DNA purification and quantification
The stored plasma samples were thawed at 4°C and centrifuged 
at 14000 rpm for 15 min at 4°C to remove residual precipitated 
cellular components. The cfDNA was purified using a QIAamp 
Circulating Nucleic Acid Kit (Qiagen, Valencia, CA, USA) ac-
cording to the manufacturer’s instructions. Briefly, 1 mL of plas-
ma was mixed with 0.1 mL of proteinase K and 0.8 mL of buffer 
ACL. After incubation at 60°C for 30 min, 1.8 mL of buffer ACB 
was added, vortexed, and incubated on ice for 5 min. The mix-
ture was filtered through the column. The bound cfDNA was 
washed with 600 µL of buffer AW1, 750 µL of buffer AW2, and 
finally 750 µL of ethanol. To elute the cfDNA, 30 µL of elution 
buffer AVE was added to the tube and incubated for 3 min at 
room temperature prior to a final centrifugation at 14000 rpm 
for 1 min. The concentration of plasma cfDNA was spectropho-
tometrically evaluated using an ultraviolet-visible spectropho-
tometer (NanoDrop 2000, Thermo Fisher Scientific Inc., Drei-
eich, Germany).
Statistical analysis
For categorical variables, a chi-square test was performed, and 
linear-by-linear association analysis was performed to calcu-
late linear relationships for more than two groups. Student’s t-
test was used to compare differences in the mean values of 
continuous variables between the two groups. Area under re-
ceiver-operating characteristic (ROC) curve (AUC) was used 
to determine the optimal cut-off value of plasma cfDNA levels. 
Progression-free (PF), intrahepatic failure-free (IHFF), and lo-
cal control (LC) rates were calculated from the date of first RT 
to the date of first progression: the events were defined as pro-
gression to any site for PF rate, as progression within the liver 
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either inside or outside of the RT field for IHFF rate, and as 
progression inside the RT field for LC rate. Survival rates were 
estimated using the Kaplan-Meier estimation method. The 
log-rank test was used to assess survival differences between 
the groups. A multivariate Cox proportional hazards regression 
model was used to examine the associated effects of potential 
prognostic factors found to be significant in univariate analy-
sis. p-values (in two-sided tests) ≤0.05 were considered statis-
tically significant. Statistical analyses were performed using 
SPSS, version 23 (IBM Corp., Armonk, NY, USA).
RESULTS
Patient and treatment characteristics of the whole cohort
For the entire cohort, HCC was related to hepatitis B virus in 
76.4% of cases, hepatitis C virus in 16.4% of cases, and non-vi-
ral origins in 7.3% of cases. A total of 30% of patients had mul-
tiple tumors, with 77% of them having tumors larger than 2 cm 
and 31.9% having portal vein tumor thrombus (PVTT) (9.1% 
in the portal trunk, 20% in first-order branch, and 1.8% in sec-
ond-order branch). There were no patients with extrahepatic 
metastatic disease, except for regional LN metastases identi-
fied in three patients (5.5%). Thus, 14 patients had mUICC stage 
I tumors, 13 had mUICC stage II tumors, 14 had mUICC stage 
III tumors, and 14 had mUICC stage IV tumors. 
Of the 55 total patients, 34 patients (61.8%) received CFRT 
with a median total dose of 46.8 Gy (range: 45−60 Gy) and a 
median fractionated dose of 1.8 Gy (range: 1.8−3 Gy), whereas 
21 patients (38.2%) received SBRT with 60 Gy in four fractions. 
The median biologically effective dose (BED) was 62.5 Gy 
(range: 53.1−150 Gy) for the entire cohort. The median BED of 
the CFRT group was 54.2 Gy (range: 53.1−78 Gy). The BED of 
SBRT group was the same for all patients at 150 Gy. Concurrent 
chemoradiotherapy was administered to 28 patients (50.9%) 
who were treated with CFRT. CFRT was used as first therapy 
in most of the patients (82.4%), while SBRT was used mainly 
Table 1. Patient Characteristics according to Pre-treatment Cell-Free 
DNA Levels
Variable
Total
n=52 (%)
LDNA
(<33.65 ng/mL)
n=26 (%)
HDNA
(≥33.65 ng/mL)
n=26 (%)
p
value
Age, median
  (range) 
59.5
(40−88)
0.579
<60 26 (49) 14 (53.8) 12 (46.2)
≥60 26 (50) 12 (46.2) 14 (53.8)
Sex 0.482
Female 10 (19.2)   6 (23.1)   4 (15.4)
Male 42 (80.8) 20 (76.9) 22 (84.6)
Cirrhosis 0.250
No 16 (30.8)   9 (34.6)   7 (26.9)
Yes 36 (69.2) 17 (65.4) 19 (73.1)
Alcohol 0.773
No 33 (63.5) 16 (61.5) 17 (65.4)
Yes 19 (36.5) 10 (38.5)   9 (34.6)
Etiology 0.247
Non-B, Non-C   4 (7.7)   2 (7.7)   2 (7.7)
B-viral 40 (76.9) 18 (69.2) 22 (84.6)
C-viral   8 (15.4)   6 (23.1)   2 (7.7)
Pre-treatment 0.357
 No 30 (57.7) 13 (50.0) 17 (65.4)
TACE 15 (28.8)   8 (30.8)   7 (26.9)
Surgery+TACE   4 (7.7)   2 (7.7)   2 (7.7)
RFA+TACE   3 (5.8)   3 (11.5)   0 (0.0)
Tumor multiplicity 0.139
Single 35 (67.3) 20 (76.9) 15 (57.7)
Multiple 17 (32.7)   6 (23.1) 11 (42.3)
Tumor size (cm) 0.017
≤2 11 (21.2)   9 (34.6)   2 (7.7)
>2 41 (78.8) 17 (65.4) 24 (92.3)
PVTT 1.000
No 35 (67.3) 18 (69.2) 17 (65.4)
Second-order 
  branch
  1 (1.9)   0 (0.0)   1 (3.8)
First-order branch 11 (21.2)   5 (19.2)   6 (23.1)
Portal trunk   5 (9.6)   3 (11.5)   2 (7.7)
LN metastasis 1.000
Negative 49 (94.2) 25 (96.2) 24 (92.3)
Positive   3 (5.8)   1 (3.8)   2 (7.7)
mUICC stage 0.049
I 12 (23.1) 10 (38.5)   2 (7.7)
II 12 (23.1)   5 (19.2)   7 (26.9)
III 14 (26.9)   5 (19.2)   9 (34.6)
IV 14 (26.9)   6 (23.1)   8 (30.8)
CTP class 1.000
A 46 (88.5) 23 (88.5) 23 (88.5)
B   6 (11.5)   3 (11.5)   3 (11.5)
Viral DNA titer (IU/mL) 1.000
≤20000 25 (69.4) 10 (66.7) 15 (71.4)
>20000 11 (30.6)   5 (33.3)   6 (28.6)
Table 1. Patient Characteristics according to Pre-treatment Cell-Free 
DNA Levels (continued)
Variable
Total
n=52 (%)
LDNA
(<33.65 ng/mL)
n=26 (%)
HDNA
(≥33.65 ng/mL)
n=26 (%)
p
value
AFP (ng/mL) 0.405
≤50 25 (48.1) 14 (53.8) 11 (42.3)
>50 27 (51.9) 12 (46.2) 15 (57.7)
PIVKA-II (mAU/mL) 0.211
≤2000 38 (73.1) 21 (80.8) 17 (65.4)
>2000 14 (26.9)   5 (19.2)   9 (34.6)
LDNA, low DNA; HDNA, high DNA; TACE, transcatheter arterial chemoem-
bolization; RFA, radio-frequency ablation; PVTT, portal vein tumor thrombosis; 
LN, lymph node; mUICC, modified Union for International Cancer Control; CTP 
class, Child-Turcotte-Pugh class; AFP, alpha-fetoprotein; PIVKA-II, protein in-
duced by vitamin K absence or antagonist-II.
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as salvage therapy (90.5%). With regard to baseline character-
istics, the CFRT group tended to have multiple and larger tu-
mors (p=0.007 and p=0.002, respectively), PVTT (p<0.001), 
advanced stage disease (p<0.001), and higher protein induced 
by vitamin K absence or antagonist II (PIVKA-II) (p=0.006); 
meanwhile, more patients in the SBRT group had a history of 
previous treatment (p<0.001).
Patient characteristics and clinical features according 
to pre-RT cfDNA levels
Table 1 shows patient and clinical characteristics according to 
pre-treatment cfDNA levels. Pre-RT cfDNA levels were avail-
able for 52 of 55 patients. A cut-off value of 33.65 ng/mL was 
obtained using ROC curve analysis (AUC=0.645, sensitivity= 
0.706, specificity=0.600). Patients were grouped according to 
their pre-RT cfDNA level, applying the optimal cut-off value of 
33.65 ng/mL for low-DNA (LDNA, n=26) and high-DNA 
(HDNA, n=26) groups. There was no difference in other base-
line characteristics, except that the pre-RT HDNA group tend-
ed to have larger tumors (p=0.017) and more patients with ad-
vanced stage HCC (mUICC stage III−IV) than the pre-RT LDNA 
group (p=0.049). When comparing the amount of viral titers 
and tumor markers according to the pre-RT cfDNA levels, pre-
RT viral titers, alpha-fetoprotein (AFP), and PIVKA-II were not 
significantly different between the pre-RT LDNA group and 
HDNA group (p=1.000, p=0.405, and p=0.211, respectively) 
(Table 1).
Treatment response according to post-RT cfDNA levels
The maximal treatment response was assessed according to 
the modified Response Evaluation Criteria in Solid Tumors.15 
Patients who achieved a complete response or partial re-
sponse were considered to have a radiographic response of ir-
radiated lesions. The optimal cut-off value of 37.25 ng/mL was 
obtained using ROC curve analysis (AUC=0.687, sensitivi-
ty=0.733, specificity=0.600), and patients were divided into 
post-RT LDNA and HDNA groups, according to the cut-off val-
ue. The treatment response was significantly better in the post-
RT LDNA group than the post-RT HDNA group (81.8% vs. 
47.8%, p=0.017).
Pre- and post-RT cfDNA levels in responders and 
non-responders
cfDNA levels were compared between the responders and 
nonresponders at baseline and after RT (Fig. 1). The mean cfD-
NA values at baseline were similar for both groups (responders 
vs. nonresponders: 39.5 vs. 39.6 ng/mL, p=0.988), but signifi-
cantly different after RT (responders vs. nonresponders: 35.9 
vs. 56.1 ng/mL, p=0.002).
Survival outcome according to post-treatment cfDNA 
levels 
Oncologic outcomes included overall survival (OS), PF, IHFF, 
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ter radiotherapy according to treatment response. A positive response 
was defined as a complete response or partial response. A negative 
response was defined as stable disease or progressive disease. RT, ra-
diotherapy; cfDNA, cell-free DNA.
and LC rates according to post-RT cfDNA levels (Fig. 2). The 
OS and PF rates were not significantly different between the 
post-RT LDNA and post-RT HDNA groups (p=0.145 and 
p=0.257, respectively) (Fig. 2A and B). Patients in the post-RT 
HDNA group had significantly lower IHFF and LC rates than 
patients in the post-RT LDNA group (p=0.035 and p=0.006)
(Fig. 2C and D). 
In subgroup analysis, patients who received CFRT were an-
alyzed separately from those who received SBRT (Fig. 3). Al-
though IHFF rates were not significantly different according 
to the amount of post-RT cfDNA in either subgroup (Fig. 3A 
and C), the post-RT LDNA group had a better LC rate than the 
post-RT HDNA group within the SBRT group (p=0.041) (Fig. 
3B) and the CFRT group (p=0.046) (Fig. 3D).
Prognostic factors for OS, PF, IHFF, and LC rates
At a median follow-up of 20.2 months (range: 1.7−66.8 months), 
the median OS was 29.1 months, and the median PF, IHFF, and 
LC periods were 10.1, 11.7, and 40.7 months, respectively. Table 
2 shows the results of univariate and multivariate analysis of 
IHFF and LC rates. The presence of cirrhosis, multiple tumors, 
and high levels of post-RT cfDNA were significant factors as-
sociated with lower IHFF rates in univariate analysis, while 
mUICC stage showed borderline significance. Among these, 
the presence of cirrhosis [p=0.006, adjusted hazard ratio (HR) 
4.656, 95% confidence interval (CI) 1.543−14.052] and post-
RT cfDNA level (p=0.036, HR 2.405, 95% CI 1.059−5.460) re-
mained significant after adjustment for other factors. Regard-
ing the LC rate, tumor multiplicity, mUICC stage, BED, and pre- 
and post-treatment cfDNA levels were identified as significant 
prognostic factors for LC rate in univariate analysis. After mul-
tivariate analysis, no factors remained statistically significant 
for LC rate.
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The factors correlated with OS and PF rate are depicted in 
Table 3. In univariate analysis for OS, tumor multiplicity, tumor 
size, mUICC stage, presence of PVTT, levels of AFP and PIV-
KA-II, and BED were significant factors, and tumor multiplici-
ty remained significant after adjusting for covariates (p=0.046, 
HR 2.737, 95% CI 1.019−7.355). Despite the presence of multi-
ple tumors, advance mUICC stage showed significant correla-
tion with poor PF rate in univariate analysis, and multivariate 
analysis revealed no significant factor for PF rate. 
DISCUSSION
Since the first description of cell-free nucleic acids in 1948,16 
many studies have attempted to clarify the association between 
cell-free nucleic acids and various diseases.17 Although the re-
lease mechanisms of cell-free nucleic acids are not fully un-
derstood, cfDNA (a cell-free nucleic acid) is thought to result 
from apoptosis, necrosis, or active secretion from cells into 
circulating blood.18 cfDNA has been investigated as a potential 
novel biomarker for the diagnosis and surveillance of various 
cancers, since the abnormalities of cfDNA were identified in 
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patients with cancer. These abnormalities include both quan-
titative and qualitative changes. The quantitative changes in-
clude an increased amount of cfDNA in cancer patients, com-
pared to normal healthy controls.19 The qualitative changes 
include specific point mutation, loss of heterozygosity, DNA 
methylation, integrity alterations, and allelic imbalances in 
DNA.2 
Compared to already established biomarkers, the use of cfD-
NA as a biomarker has several advantages in liver cancer. First, 
cfDNA is easily obtainable and can be collected repeatedly for 
follow-up through noninvasive methods. In addition, unlike 
samples obtained by invasive biopsy on focal lesions, samples 
that are extracted from blood, including cfDNA, can provide 
information on the overall state of patients. However, there are 
also disadvantages to the use of cfDNA. As described by Tang, 
et al.,20 cfDNA is only present in trace amounts in serum, and 
efficient isolation is difficult. In addition, factors other than the 
tumor itself, such as inflammatory responses, may also affect 
the amount of cfDNA. Especially for HCC, in which chronic in-
flammation from hepatitis B or C virus may coexist, interpre-
tation should be made cautiously.21
Although the amount of cfDNA has been reported to be as-
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sociated with tumor burden or prognosis in many studies,22-25 
limited research is available in the field of radiation oncology. 
In a single-institution prospective study of early-stage non-
small-cell lung cancer, Bortolin, et al.11 reported that higher lev-
els of cfDNA were associated with unfavorable survival out-
comes in patients who underwent SBRT. In a study of patients 
with head and neck squamous carcinoma, Mazurek, et al.12 
reported that higher levels of cfDNA were observed in patients 
with advanced N stage and overall. Woo, et al.13 reported that 
cfDNA declined significantly after concurrent chemoradio-
therapy in a study of patients with pancreatic cancer. 
Several studies on cfDNA have included patients with liver 
cancer. Specifically, the amount of cfDNA and genetic altera-
tion detected in cfDNA were reported as potential biomarkers 
for diagnosis in patients with HCC, either solely or in combi-
nation with AFP (a known biomarker).26 In addition, several 
studies have reported that elevated levels of cfDNA after radi-
cal resection for HCC are associated with poor patient surviv-
al.25,27 However, it is still unclear whether plasma or serum 
cfDNA can be used as a predictive marker in HCC for treat-
ment options other than surgery. To the best of our knowl-
edge, this is the first study to investigate the value of cfDNA as 
a biomarker in patients with HCC who underwent RT. 
The results of our study showed that cfDNA levels have clin-
ical significance in pre- and post-treatment settings. First, in a 
pre-treatment setting, tumor sizes were larger in the HDNA 
group than in the LDNA group; furthermore, the proportion 
of patients with advanced tumors was greater. These findings 
Table 2. Univariate and Multivariate Analyses of IHFF and LC Rates
Variable
UVA (IHFF rate) MVA (IHFF rate) UVA (LC rate) MVA (LC rate)
HR (95% CI) p value
Adjusted 
HR
(95% CI) p value HR (95% CI) p value
Adjusted 
HR
(95% CI) p value
Age 1.254 0.628−2.506 0.521 1.197 0.504−2.844 0.683
Sex
Female 1 1
Male 1.122 0.462−2.724 0.800 2.683 0.626−11.493 0.184
Cirrhosis
Absent 1 1 1
Present 2.497 1.057−5.900 0.037 4.656 1.543−14.052 0.006 1.581 0.576−4.336 0.374
Tumor multiplicity
Single 1 1 1 1
Multiple 2.665 1.292−5.496 0.008 2.228 0.756−6.571 0.146 5.872 2.392−14.418 <0.001 3.292 0.772−14.045 0.107
Tumor size (cm)
≤2 1 1
>2 0.802 0.368−1.749 0.580 2.509 0.736−8.552 0.141
mUICC stage
I−II 1 1 1 1
III−IV 1.831 0.914−3.669 0.088 1.499 0.497−4.523 0.472 5.202 1.882−14.382 0.001 1.081 0.407−2.872 0.876
PVTT
No 1 1
Yes 1.046 0.506−2.162 0.904 1.819 0.778−4.252 0.167
Viral titer 1.150 0.469−2.819 0.760 1.971 0.724−5.370 0.184
AFP 0.975 0.491−1.934 0.941 1.171 0.506−2.712 0.712
PIVKA-II 0.752 0.326−1.736 0.504 1.433 0.583−3.525 0.433
BED (Gy)
<100 1 1 1
≥100 1.023 0.504−2.077 0.949 0.358 0.130−0.985 0.047 0.241 0.018−3.225 0.282
pre-RT cfDNA
<33.65 1 1 1
≥33.65 1.697 0.815−3.533 0.157 2.842 1.087−7.426 0.033 1.673 0.470−5.955 0.427
post-RT cfDNA
<37.25 1 1 1 1
≥37.25 2.293 1.036−5.076 0.041 2.405 1.059−5.460 0.036 3.908 1.371−11.142 0.011 1.963 0.566−6.805 0.288
UVA, univariate analysis; MVA, multivariate analysis; IHFF, intrahepatic failure-free; LC, local control; HR, hazard ratio; CI, confidence interval; mUICC, modified 
Union for International Cancer Control; PVTT, portal vein tumor thrombosis, AFP, alpha-fetoprotein; PIVKA-II, protein induced by vitamin K absence or antagonist-
II; BED, biologically effective dose; RT, radiotherapy; cfDNA, cell-free DNA.
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are presumed to be because the tumor bulk itself, which shows 
a positive correlation with cfDNA levels, as suggested in previ-
ous studies.28-30 In the post-treatment setting, the LDNA group 
showed significantly better tumor response and LC than the 
HDNA group. 
The relationships between elevated cfDNA levels and poor 
prognosis have been reported for a variety of carcinomas. In-
vestigations of the kinetics of circulating tumor-derived DNA 
in serum or plasma revealed that the amounts of cfDNA were 
found to increase at the beginning of RT and to decrease to or 
below initial levels by the end of treatment.12,13,19,31 Therefore, 
the persistent elevation of cfDNA after treatment completion 
may indicate the presence of remnant lesions or progression 
in other sites.32,33 After adjusting for other factors, a high post-
RT cfDNA level was revealed to be an independent factor for 
poor intrahepatic tumor control.
Intrahepatic metastasis and recurrence, which is common 
in patients with HCC, are known to have a significant impact 
on prognosis.34-36 In an analysis of failure patterns in the pres-
ent study, among 37 patients with failures, intrahepatic failure 
as a first event was observed in 29 (78.4%) patients; synchro-
nous intrahepatic and extrahepatic failure occurred in 2 
(5.4%) patients. Only 7 patients (18.9%) developed extrahe-
patic failure as a first failure event. Because intrahepatic fail-
ures are major patterns of failure, the importance of achieving 
LC in patients with HCC cannot be overemphasized to pre-
vent the further progression of intrahepatic metastases and to 
improve the overall prognosis of patients. In summary, in the 
Table 3. Univariate and Multivariate Analyses of OS and PF Rates
Variable
UVA (OS) MVA (OS) UVA (PF rate) MVA (PF rate)
HR (95% CI) p value
Adjusted 
HR
(95% CI) p value HR (95% CI) p value
Adjusted 
HR
(95% CI) p value
Age 0.573 0.254−1.292 0.180 1.104 0.574−2.124 0.766
Sex
Female 1 1
Male 1.351 0.461−3.955 0.584 1.345 0.560−3.234 0.508
Cirrhosis
Absent 1 1
Present 1.656 0.654−4.197 0.288 2.120 0.978−4.599 0.057
Tumor multiplicity
Single 1 1 1 1
Multiple 6.754 2.891−15.781 <0.001 2.737 1.019−7.355 0.046 3.209 1.616−6.373 0.001 2.382 0.980−5.791 0.055
Tumor size (cm)
≤2 1 1 1
>2 9.171 1.237−67.968 0.030 1.656 0.156−17.587 0.676 0.971 0.451−2.088 0.939
mUICC stage
I–II 1 1 1 1
III–IV 9.261 3.129−27.411 <0.001 3.723 0.801−17.312 0.094 2.442 1.250−4.771 0.009 1.538 0.642−3.681 0.334
PVTT
No 1 1 1
Yes 3.418 1.521−7.679 0.003 0.564 0.204−1.560 0.270 1.306 0.670−2.547 0.433
Viral titer 2.295 0.933−5.644 0.070 1.077 0.464−2.501 0.862
AFP 2.387 1.042−5.472 0.040 1.151 0.470−2.820 0.759 1.205 0.631−2.298 0.572
PIVKA-II 2.921 1.305−6.537 0.009 1.306 0.551−3.096 0.544 1.437 0.708−2.916 0.315
BED (Gy)
<100 1 1 1
≥100 0.110 0.026−0.471 0.003 0.258 0.050−1.336 0.106 0.815 0.409−1.625 0.562
Pre-RT cfDNA
<33.65 1 1
≥33.65 1.295 0.580−2.894 0.528 1.630 0.821−3.236 0.163
Post-RT cfDNA
<37.25 1 1
≥37.25 1.909 0.788−4.626 0.152 1.516 0.734−3.130 0.260
UVA, univariate analysis; MVA, multivariate analysis; OS, overall survival, PF, progression-free HR, hazard ratio; CI, confidence interval; mUICC, modified Union 
for International Cancer Control; PVTT, portal vein tumor thrombosis, AFP, alpha-fetoprotein; PIVKA-II, protein induced by vitamin K absence or antagonist-II; BED, 
biologically effective dose; RT, radiotherapy; cfDNA, cell-free DNA.
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absence of a validated early predictor for treatment response 
in HCCs, these results suggest that the amount of cfDNA mea-
sured immediately after RT might hold potential as a novel, 
easy-to-use biomarker with which to predict treatment re-
sponse and the prognosis of patients. There have been some 
previous reports that showed the significance of pre-treatment 
cfDNA in predicting treatment outcome.23,25 However, in our 
study, post-RT cfDNA, not pre-RT cfDNA, was found to be pre-
dictive of IHFF, suggesting that it could be a useful marker for 
predicting local treatment response earlier (immediately after 
treatment) than regular response evaluation time (1−3 months 
after treatment).
Our study has some limitations. First, a small cohort of only 
55 patients was enrolled in our study, making it difficult to de-
rive meaningful results in our statistical analysis. Secondly, our 
study population consisted of two different prospective study 
cohorts: CFRT with concomitant chemotherapy was per-
formed for one cohort, and SBRT for the other. The heteroge-
neity of these populations, including baseline characteristics 
and treatment details, might be a confounding factor. Thirdly, 
the amount of cfDNA can be affected by other factors like 
chronic inflammation (from hepatitis B or hepatitis C) and pre-
vious treatments. To account for the effect of viral infection, we 
compared the viral titer of pre-RT LDNA and HDNA groups, 
and found no significant difference in viral titer between the 
two groups. In order to prevent fluctuations in cfDNA caused 
by previous treatment, patients who received RT after at least 
1 month (median 3 months, range 1−69 months) from previ-
ous transcatheter arterial chemoembolization (TACE) of RFA 
were included in our analysis, as cfDNA has been found to in-
crease after TACE with the highest level being detected 4 days 
after the treatment.37 Finally, this study aimed at only quanti-
tative analysis, as the first attempt to investigate the significance 
of cfDNA in HCC patients treated with RT, since the analysis 
of cfDNA can further be expanded to NGS for the comprehen-
sive genetic information of cancer.
In conclusion, quantitative analysis of cfDNA was feasible 
for our patients. This study suggests the possibility of post-RT 
cfDNA level as an early predictor for treatment response and 
LC after RT in patients with HCC. However, further prospec-
tive studies with larger populations and more homogenous pa-
tient cohorts are required to confirm this hypothesis.
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